Table 2. Baseline characteristics of the two treatment groups.
Characteristic | No. of studies | Pralidoxime group | Control group | P- value |
No. of patients | 6 | 326 | 320 | |
Age, mean (SD) | 5 | 31.5 (3.1) | 30.6 (3.6) | 0.68 |
Males/females in included studies | 5 | 193/123 | 183/126 | 0.91/ 0.75a |
No (%) of patients with DM OP poisoning | 3 | 98 (43.8) | 103 (48.5) | 0.68a |
No (%) of patients with DE OP poisoning | 3 | 95 (38.7) | 87 (36.6) | 0.93a |
No (%) of patients with severe poisoning | 6 | 162 (49.7) | 155 (48.4) | 0.66a |
Average pseudocholinesterase levels, mean (SD) IU/L | 2 | 1400.1 (589.5) | 1940.6 (320.5) | 0.64 |
Average butyrylcholinesterase levels, mean (SD) IU/L | 2 | 972.3 (565.9) | 823.6 (426.8) | 0.90 |